Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

Prognostic Analysis of Thymoma-Associated Myasthenia Gravis (MG) in Chinese Patients and Its Implication of MG Management: Experiences from a Tertiary Hospital

Authors Chen D, Peng Y, Li Z, Jin W, Zhou R, Li Y, Xu Q, Yang H

Received 23 December 2019

Accepted for publication 28 March 2020

Published 14 April 2020 Volume 2020:16 Pages 959—967

DOI https://doi.org/10.2147/NDT.S243519

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jun Chen


Di Chen, Yuyao Peng, Zhibin Li, Wanlin Jin, Ran Zhou, Yi Li, Qiushuang Xu, Huan Yang

Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China

Correspondence: Huan Yang
Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China
Email yangh69@126.com

Background: Myasthenia gravis (MG) is an autoantibody-mediated neuromuscular disorder. Approximately 10– 20% of all MG patients experience thymoma (benign tumor arising from thymus tissue). Thymectomy has been the standard of care for thymomatous myasthenia gravis (TMG). However, the clinical outcome of TMG after thymectomy has not been sufficiently studied, especially the long-term prognosis. Therefore, the aim of this study was to analyze the clinical characteristics contributing to the prognostic factors of TMG.
Methods: We reviewed 70 TMG patients in the Xiangya Hospital and classified them into the minimal manifestation (MM) group and No MM group, according to the long-term treatment outcome. MM-or-better status was defined as the goal treatment for TMG patients. We collected and analyzed the demographic data, the WHO classification of thymoma, MG-associated antibody levels, disease severity, treatment-related data as well as clinical outcome at six months. Variables selected by univariate analysis were used in the multivariate logistic regression model to identify the prognostic factors.
Results: The differences in clinical outcome at six months and worst QMGS were significant, while the differences in other factors were insignificant between groups. Clinical outcome at six months (OR=23.5 95% CI 2.4– 231.5, P=0.007) and dyspnea before thymectomy (OR=0.2, 95% CI 0.03– 0.75, P=0.021) were identified as the prognostic factors of long-term treatment.
Conclusion: Demographic and clinical features were similar in TMG patients treated at our hospital. The early achievement of MM-or-better status may indicate a good outcome in the long term. Dyspnea before thymectomy appears to associate with a poor prognosis.

Keywords: myasthenia gravis, thymoma, the WHO classification, clinical presentation, prognostic factors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]